Skip to Content

Curaleaf Holdings Inc CURA Stock Quote

| Rating as of

Morningstar‘s Stock Analysis CURA

Valuation
Currency in CAD
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price

INVESTOR

5-Star Price

INVESTOR

Economic Moat

INVESTOR

Capital Allocation

INVESTOR

Robust Q2 Shows Why Curaleaf’s Stock Has Fallen Less than Peers, but Stock Remains Very Undervalued

Analyst Note

| Kristoffer Inton |

Any inflationary cost pressure seems to be in Curaleaf’s rearview mirror, as second-quarter revenue grew 8% sequentially to $338 million and adjusted EBITDA margin expanded 220 basis points to 25.6%. In comparison, first-quarter revenue declined 2% sequentially and adjusted EBITDA margin contracted 150 basis points.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics CURA

Company Profile CURA

Business Description

Curaleaf is headquartered in Wakefield, Massachusetts, and cultivates and sells medicinal and recreational cannabis in the U.S. The company has operations in 22 states, including the assets from the Cura Select and Grassroots acquisitions. Its brands include Curaleaf, UKU, Select, and Grassroots. The company acquired EMMAC Life Sciences in March 2021, beginning its foray into the global medical market in competition with Canadian cannabis producers.

Contact
301 Edgewater Place #110, Suite 405
Wakefield, MA, 01880
T +1 781 451-0150
Industry Drug Manufacturers - Specialty & Generic
Most Recent Earnings Jun 30, 2022
Fiscal Year End Dec 31, 2022
Stock Type
Employees 5,671